Co-Authors
This is a "connection" page, showing publications co-authored by STACEY BERG and SUSAN BLANEY.
Connection Strength
3.773
-
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol. 2011 Jan 20; 29(3):316-23.
Score: 0.378
-
Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2010 Jul 15; 55(1):119-22.
Score: 0.367
-
Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemother Pharmacol. 2007 May; 59(6):743-7.
Score: 0.281
-
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res. 2005 Aug 15; 11(16):5981-3.
Score: 0.261
-
Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Aug; 54(2):127-30.
Score: 0.239
-
Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jul; 54(1):85-8.
Score: 0.237
-
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer. 2020 02; 67(2):e28073.
Score: 0.175
-
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer. 2018 08; 65(8):e27066.
Score: 0.157
-
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer. 2013 Apr; 60(4):627-32.
Score: 0.107
-
Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer. 2012 Mar; 58(3):362-5.
Score: 0.099
-
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42.
Score: 0.086
-
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemother Pharmacol. 2009 Jul; 64(2):335-40.
Score: 0.082
-
Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer. 2008 Oct; 51(4):504-8.
Score: 0.081
-
Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer. 2008 Apr; 50(4):757-60.
Score: 0.078
-
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2008 Jul; 62(2):355-61.
Score: 0.076
-
Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol. 2008 Apr; 61(4):647-52.
Score: 0.074
-
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23.
Score: 0.066
-
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20; 23(15):3376-82.
Score: 0.064
-
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 01; 23(7):1555-63.
Score: 0.063
-
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004 Dec 01; 22(23):4804-9.
Score: 0.062
-
Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
Score: 0.062
-
Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer Drugs. 2004 Oct; 15(9):883-8.
Score: 0.061
-
Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clin Cancer Res. 2004 Aug 01; 10(15):5072-5.
Score: 0.061
-
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res. 2004 Apr 01; 10(7):2525-9.
Score: 0.059
-
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jun; 53(6):527-32.
Score: 0.059
-
Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jan; 53(1):39-42.
Score: 0.057
-
Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. Cancer Chemother Pharmacol. 2003 Nov; 52(5):417-23.
Score: 0.056
-
Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7.
Score: 0.054
-
Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol. 2002 Feb; 24(2):130-3.
Score: 0.051
-
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 07 01; 27(13):3543-3548.
Score: 0.048
-
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019 06 01; 25(11):3229-3238.
Score: 0.042
-
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Sep; 55(3):440-5.
Score: 0.023
-
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008 Jun; 13(6):679-89.
Score: 0.020
-
Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):549-53.
Score: 0.019
-
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8.
Score: 0.019
-
Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007 May; 59(6):847-53.
Score: 0.018
-
Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9.
Score: 0.016
-
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res. 2002 Jul; 8(7):2437-42.
Score: 0.013